BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 8, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2019

View Archived Issues

FDA clears IND for NantKwest's CD19.t-haNK cell therapy

Read More

GlaxoSmithKline initiates phase I study of HBV therapeutic vaccines

Read More

Pfizer initiates phase II study of PF-06700841 topical cream for atopic dermatitis

Read More

First-in-human data presented for TAS-119

Read More

TVB-2640 in combination with bevacizumab results in promising PFS in patients with recurrent GBM

Read More

Phase I data for CC-90010 in patients with advanced solid tumors and non-Hodgkin's lymphoma

Read More

Clinical study foreseen for Immunic's autoimmune disease candidate IMU-935

Read More

Microbiome metabolism influences drug responses

Read More

Novel ruthenium(II) complex induces apoptosis and inhibits angiogenesis in tumor animal models

Read More

Rifamycin SV-MMX evaluated in phase II study for acute uncomplicated diverticulitis

Read More

Promising results of phase I trial of CAL-02 in severe community-acquired pneumococcal pneumonia

Read More

TXNRD1 blockade found to play protective role in acute lung injury

Read More

New gene variants found to protect against osteoporosis in patients with Gaucher's disease

Read More

Phase III ELEVATE-TN trial of Calquence in previously untreated CLL meets primary endpoint

Read More

Asclepius initiates phase I/II study of BCMA CAR-NK cells in relapsed/refractory multiple myeloma

Read More

Partial response observed in ongoing phase II study of BN-Brachyury for chordoma

Read More

Phase III study of Ninlaro in systemic AL amyloidosis misses first of two primary endpoints

Read More

Vaccitech initiates phase IIb study of MVA-NP+M1 universal flu vaccine in Belgium

Read More

Concert Pharmaceuticals presents phase I preliminary data for CTP-692

Read More

Novartis discovers HBsAg secretion inhibitors

Read More

New mGlu2 negative allosteric modulators synthesized at Sumitomo Dainippon Pharma

Read More

Senju Pharmaceutical synthesizes new PAC1 and/or VPAC1 and/or VPAC2 receptor ligands

Read More

Hepagene Therapeutics patents MEK kinase 5 inhibitors

Read More

Metabomed identifies acetyl-coenzyme A synthetase, cytoplasmic inhibitors

Read More

InflaRx reports topline results from phase IIb SHINE study of IFX-1 in hidradenitis suppurativa

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 5, 2025.
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing